4//SEC Filing
Hu Edward 4
Accession 0000899243-21-011592
CIK 0001734517other
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 4:52 PM ET
Size
12.8 KB
Accession
0000899243-21-011592
Insider Transaction Report
Form 4
Hu Edward
Director
Transactions
- Disposition to Issuer
Common Stock
2021-03-13$53.00/sh−3,953,118$209,515,254→ 0 total(indirect: Held by 6 Dimensions Capital, L.P.) - Disposition to Issuer
Common Stock
2021-03-13$53.00/sh−208,059$11,027,127→ 0 total(indirect: Held by 6 Dimensions Affiliates Fund, L.P.) - Disposition to Issuer
Stock Option (right to buy)
2021-03-15−26,210→ 0 totalExercise: $19.00Exp: 2029-10-01→ Common Stock (26,210 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-03-15−7,358→ 0 totalExercise: $48.96Exp: 2030-06-18→ Common Stock (7,358 underlying)
Footnotes (3)
- [F1]Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger, each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
- [F2]Mr. Hu is Managing Partner of 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P. and may be deemed to beneficially own the shares held by 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P. Mr. Hu disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.
Documents
Issuer
Viela Bio, Inc.
CIK 0001734517
Entity typeother
Related Parties
1- filerCIK 0001313786
Filing Metadata
- Form type
- 4
- Filed
- Mar 14, 8:00 PM ET
- Accepted
- Mar 15, 4:52 PM ET
- Size
- 12.8 KB